This past decade has been marked by rapid advances in our understanding of the pathogenesis of many musculoskeletal disorders. Parallel to these events, there have been remarkable advances in our therapeutic options for many patients. Now, with a decade of experience with many of these novel agents, we can now reflect on which of these approaches have been successful, which have been unsuccessful, and, more importantly, better understand the reasons for the successes and failures. In this section of Clinical Therapeutics, there is a comprehensive review of the state of the art of our new therapies as they apply to rheumatoid arthritis (RA), spondyloarthropathies, vasculitis associated with anti-neutrophil cytoplasmic antibodies (ANCA), and pediatric clinical research.
There is no doubt that the treatment of adults with RA has dramatically been altered by the introduction of inhibitors of tumor necrosis factor (TNF). Three TNF inhibitors (adalimumab, etanercept, and infliximab) have now been approved for the treatment of RA. The most important recent data suggest that many patients who receive the combination of an anti-TNF agent plus methotrexate (MTX) have a superior response as measured by improvement in signs and symptoms and radiographic damage.
The challenge now remains to identify which patients need to be treated early with the combination and which patients should be receiving monotherapy with either the anti-TNF agents or MTX. In addition, it still remains to be shown that the combination of MTX plus anti-TNF therapy is superior to more traditional combination of other diseasemodifying antirheumatic drugs (DMARDs) such as MTX, hydroxychloroquine, and sulfasalazine. The studies addressing this important question are currently in progress.
In addition, it is now becoming more obvious with data that are emerging from long-term registries a large percentage of patients who initially receive anti-TNF therapy no longer continue that therapy after 2 to 5 years. There are numerous reasons, but some include the possibility of immunogenicity of the administered protein, other proinflammatory mechanisms of tissue inflammation, and mechanisms of tissue damage are operative independent of TNF. Thus, there are significant unmet needs and opportunities to continue our search for better understanding of the pathogenesis of RA as well as understanding the mechanisms by which patients respond to anti-TNF therapies and, equally important, understand why those who initially respond and then subsequently lose that response.
Although there are numerous potential molecular targets at this time, the targets that have received the most attention, and from which we have clinical trial data, include those that block interleukin (IL)-6, costimulatory pathway, and B cells. These three new targets are reviewed in detail by Choy. Multiple other cytokines (IL-12, IL-13, IL-17, IL-18, etc.) have been shown to potentially attractive targets with biologic therapies. IL-6 is a pleotropic cytokine that has multiple pro-inflammatory activities. Several clinical trials have shown that MRA (atlizumab) can demonstrate significant improvements in signs and symptoms in patients with RA [1] [2] [3] . Pivotal phase III studies are now under way to better define the efficacy and also the long-term safety profile of this novel biologic agent. Some dose-related adverse events have been reported in studies to date, including elevated liver enzymes, decreased white blood cell counts, and a rise in serum cholesterol.
Abatacept is a costimulatory blocker that has now been evaluated in several placebo-controlled trials [4] [5] [6] . Abatacept selectively blocks the engagement of cytotoxic T-lymphocyte-associated protein 4 with CD80/CD86, which provide the essential secondary costimulatory signals for T cell activation. It selectively inhibits the function of T cells but does not deplete the circulating T cells.
Abatacept has been studied in patients who have been MTX partial responders and in patients who have responded partially or not at all to anti-TNF therapy.
Another exciting area in the field of RA has been the role of B cells. Data have emerged in patients with RA about the role of rituximab, a specific inhibitor of CD20
Pivotal phase III studies are in progress to determine the long-term safety and efficacy of this agent. In addition, other inhibitors of B cell function are in early development at this stage.
Although the major impact seen to date in the use of biologic response modifiers has been with adults, there have been an equal number of improvements or breakthroughs in our therapeutic opportunities in children with musculoskeletal disorders. Drs. Ruth and Lovell review the new information on juvenile systemic lupus erythematosus, juvenile idiopathic arthritis, and juvenile dermatomyositis.
There is a special emphasis on strategies to improve the health-related quality of life in children with these musculoskeletal disorders. Perhaps one of the most important findings has been the data demonstrating that in children who do not respond to oral methotrexate, either because of inefficacy or toxicity, the use of subcutaneous methotrexate has a very high likelihood of success without any significant increased toxicity [8] . Understanding compliance and administering adequate and proper doses to children is a critically important issue. We have the ability to use methotrexate at its maximum effective dose and combine that with other agents such as anti-TNF agents. For now, we have the opportunity to significantly affect the quality of life and functioning of our children who have juvenile RA.
A major finding over the past several years has been the consistent data that patients with RA have a shortened lifespan. Further research has determined that a major cause of this is an increase in cardiovascular disease in patients with this chronic inflammatory condition. Drs. Snow and Mikuls review the most recent information regarding this area of rapidly developing news with regard to the mechanisms as well as potential therapeutic ways to prevent adverse cardiovascular outcomes in RA patients. The increased cardiovascular morbidity and mortality in RA are most likely multifactorial. The most likely explanation is that the ongoing systemic inflammation in the joints leads to dysfunction in endothelial cells and premature arthrosclerosis. Understanding the pathogenesis of arthrosclerosis is obviously important to understanding the role of the immune system in this process. In addition, many patients with RA have significant comorbid conditions that may predispose them to cardiovascular risks. Finally, several medications used to treat RA may contribute to the cardiovascular risks. The role of methotrexate, glucocorticoids, and NSAIDs in the premature cardiovascular events in RA patients remains an area of investigation.
One key unanswered question at this time is whether our new treatment paradigm of early aggressive treatment of RA with disease-modifying drugs alters the cardiovascular outcome. Indeed, in a recent study by Krishnan et al.
, there seems to be evidence that the incidence in birth cohorts of RA patients, investigators noted temporal improvements in myocardial infarction-related mortality. Additional attention is needed in this area to better define the cost effectiveness of long-term therapies with these new aggressive approaches.
Finally, data have emerged about the role of statins and their ability to be anti-inflammatory agents. Thus, in addition to lowering cholesterol levels, statins have the potential to be anti-inflammatory agents and could provide a unique opportunity to further our potential to improve the cardiovascular risks in patients with RA. The most compelling and comprehensive study has been a trial of atorvastatin agent in which RA patients were treated with atorvastatin compared with placebo for 6 months [10] . There were significant improvements in inflammatory markers as well as the expected declines in cholesterol low-density lipoprotein and triglycerides.
The therapeutic approach to spondoyloarthropathies has been markedly altered in the past few years with the availability of TNF inhibitors. Drs. Anandarajah and Ritchlin review the rapidly advancing field of new therapies for ankylosing spondylitis and psoriatic arthritis from some of the recent published data and the recent approval of these agents by the US Food and Drug Administration and European authorities. All three anti-TNF therapies (etanercept, adalimumab, and infliximab) are approved, or are being studied in clinical trials for approval, for both ankylosing spondylitis and psoriatic arthritis [11] [12] [13] .
Although it has not yet been demonstrated by studies, some of the same remarkable clinical outcomes can be expected to occur with the spondyloarthropathies that have been seen with RA. Thus, it will be important that we better study the factors that predict good response and what combination of therapies, whether additional DMARDs plus anti-TNF agents or some other combination, would be most useful to treat these seronegative spondyloarthropathies. In this same context, several other targets are attractive for therapy of both ankylosing spondylitis and psoriatic arthritis; they include IL-1, costimulatory pathway, and adhesion molecules, to name a few.
The spectrum of vasculitides has also been an area of major advances in our understanding of pathogenesis and thus the ability to provide better therapies. Dr. Stone outlines the recent pivotal studies of three randomized controlled trials that have been performed and reviews the results of these important studies that highlight the lessons learned from targeting patients with ANCA-associated vasculitis [14,15 •• ,16] . The major conclusions from these three trials are as follows:
1. Azathioprine plus maintenance-dose steroids is as effective as cyclophosphamide plus maintenance steroids in sustaining disease remission in ANCAassociated vasculitis. 2. Methotrexate is as effective as cyclophosphamide for the induction of remission within 6 months of treatment; however, there were more relapses in the methotrexate-treated group than in the cyclophosphamidetreated group after initial induction. 3. Etanercept was not superior to placebo for the maintenance of disease remission in Wegener's granulomatosis.
The lessons learned from these extremely important, well designed, multicenter, international collaborative studies will be fruitful for a better understanding of the pathogenesis of these diseases and in developing new targets.
